NTT Electronics starts shipping 140 Gbaud High-performance Coherent DSP
6.3.2023 21:00:00 EET | Business Wire | Press release
NTT Electronics, a leading supplier of coherent Digital Signal Processor (DSP) solutions to system and module manufacturers worldwide, today announced start of 140 Gbaud high-performance coherent DSP (ExaSPEED GAIA) shipment to customers. ExaSPEED GAIA achieves world's largest transmission capacity of 1.2 Tbit/s per wavelength by utilizing a programmable baud rate of up to 140 Gbaud powered by a flexible coded modulation scheme and advanced 5nm FinFET CMOS process.
“We are excited to add the ExaSPEED GAIA DSP to our product portfolio which cuts the power consumption per bit to half while doubling the baud rate over earlier product offering,” said Satoshi Shigematsu, NTT Electronics General Manager of Broadband System & Device Business Unit. “We believe this high-performance DSP will help our customers offer highly differentiated optical transmission equipment and systems”, he added.
The programmable baud rate can support very fine granularity that enables ExaSPEED GAIA to adapt to a range of links while maximizing spectral efficiency. These include short-reach data center interconnects (DCI), terrestrial metro links with cascaded ROADMs, and ultra-long-haul sub-sea links. Customers can use a wide range of 400G interfaces in 1.2T (3x400GbE) for DCI, 800G (2x400GbE) for metro and 400G (1x400GbE) for sub-sea applications. This capability helps simplify interfaces and optimize Capital/Operational expenditure. Moreover, ExaSPEED GAIA also offers fine capacity tuning in 50G increments to respond to various customer requirements.
Flexible coded modulation is the newly-developed coding scheme to efficiently implement advanced constellation shaping, forward error correction (FEC), and high-order modulation format with high performance and low power. This enables ExaSPEED GAIA to support thousands of operational modes that cover a multitude of customer's transmission links with high energy efficiency. To enhance the performance, ExaSPEED GAIA employs a number of novel compensation algorithms including nonlinear distortion compensation, adaptive fast state of polarization (SOP) tracking, fast device and transmission characteristics estimation, and ultra-long CD compensation for high-baud rate systems*. The performance of ExaSPEED GAIA can be further optimized by combining it with NTT Electronics’ industry-leading high speed coherent driver module (UHB-CDM).
"We are very impressed with the performance of NTT Electronics’ latest ExaSPEED GAIA DSP," commented Hideki Matsui, Vice Head of Photonics System Business Unit, Fujitsu Limited. “This revolutionary DSP makes our products more competitive in the market and enables us to offer innovative solutions. It opens up a new 'terabit era,' which will be a game changer in our industry,” he added.
“This state-of-the-art DSP, we believe would be key to realize the future information-centric society,” said Akio Goto, General Manager of Photonics Device Development Division, NEC Corporation. He also said, “We are excited to introduce ExaSPEED GAIA in conjunction with CDM in our DWDM products to build diverse, high-throughput and green optical networks.”
* https://group.ntt/en/newsrelease/2022/09/05/220905a.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005007/en/
Contact information
NTT Electronics Contact :
Atul Srivastava, CEO & CTO
NTT Electronics America, Inc.
Tel : +1-201-556-1770
Email : pr@nel-america.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites”30.3.2026 02:35:00 EEST | Press release
Axelspace Corporation, Meisei Electric Co., Ltd., ANA HOLDINGS INC., and JIJ Inc. are pleased to announce that their jointly proposed technology development project has been selected for Japan Aerospace Exploration Agency (JAXA)’s Space Strategy Fund under the theme “Technology to Enhance Capability of Next Generation Earth Observation Satellites.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323044518/en/ Conceptual Diagram of the project. Under this Space Strategy Fund initiative, spectrometers will be newly developed and demonstrated in orbit. In the future, the project envisions the establishment of a satellite constellation capable of observations at different times of the day. Project Summary (Planned) Technology Development Theme: Technology to Enhance Capability of Next Generation Earth Observation Satellites Project Title: Source-Specific CO2 Emission and Uptake Monitoring through Satellite Constellation and Ai
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom